Department of Health Behavior and Health Education, University of Michigan School of Public Health, Ann Arbor, Michigan 48106-1248, USA.
Genet Med. 2010 Apr;12(4):219-27. doi: 10.1097/GIM.0b013e3181cef9e1.
This study evaluates the Alzheimer disease risk perceptions of individuals who accurately recall their genetics-based Alzheimer disease risk assessment.
Two hundred forty-six unaffected first-degree relatives of patients with Alzheimer disease were enrolled in a multisite randomized controlled trial examining the effects of communicating APOE genotype and lifetime Alzheimer disease risk information.
Among the 158 participants who accurately recalled their Alzheimer disease risk assessment 6 weeks after risk disclosure, 75 (47.5%) believed their Alzheimer disease risk was more than 5% points different from the Alzheimer disease risk estimate they were given. Within this subgroup, 69.3% believed that their Alzheimer disease risk was higher than what they were told (discordant high), whereas 30.7% believed that their Alzheimer disease risk was lower (discordant low). Participants with a higher baseline risk perception were more likely to have a discordant-high risk perception (P < 0.05). Participants in the discordant-low group were more likely to be APOE epsilon4 positive (P < 0.05) and to score higher on an Alzheimer disease controllability scale (P < 0.05).
Our results indicate that even among individuals who accurately recall their Alzheimer disease risk assessment, many people do not take communicated risk estimates at face value. Further exploration of this clinically relevant response to risk information is warranted.
本研究评估了能够准确回忆其基于遗传学的阿尔茨海默病风险评估的个体的阿尔茨海默病风险感知。
246 名阿尔茨海默病患者的无病一级亲属参加了一项多中心随机对照试验,该试验旨在研究传递 APOE 基因型和终身阿尔茨海默病风险信息的效果。
在 158 名 6 周后准确回忆起其阿尔茨海默病风险评估的参与者中,有 75 名(47.5%)认为其阿尔茨海默病风险比他们获得的阿尔茨海默病风险估计值高出 5 个百分点以上。在这一分组中,69.3%的人认为他们的阿尔茨海默病风险高于他们被告知的风险(不一致高),而 30.7%的人认为他们的阿尔茨海默病风险低于他们被告知的风险(不一致低)。基线风险感知较高的参与者更有可能具有不一致高的风险感知(P < 0.05)。不一致低组的参与者更有可能携带 APOE epsilon4 阳性(P < 0.05),并且在阿尔茨海默病可控制性量表上的得分更高(P < 0.05)。
我们的结果表明,即使在能够准确回忆其阿尔茨海默病风险评估的个体中,许多人也不会完全相信所传达的风险估计值。需要进一步探索这种对风险信息的临床相关反应。